Last Updated: October 31st, 2025
We applied early economic modeling and scenario analysis to shape Health Technology Assessment (HTA) submission strategies, optimize price potential, and adapt continuously as new clinical evidence emerged.
What Is Early Modeling for Price Potential & HTA Strategy?
Our early modeling utilizes a preliminary, early cost-effectiveness Markov model to assess a product’s potential pricing outlook prior to launch. This approach forecasts how HTA bodies might assess cost per QALY, tests structural assumptions, and shapes evidence generation strategies to support access.
How Our Technology Delivers Results
We operate with practical agility, supported by a lean structure that fosters seamless collaboration and rapid resource mobilization to deliver projects efficiently. Our approach included:
Evidence generation strategy: Conducted one-way sensitivity and value of information analyses to deliver focused recommendations for evidence generation using limited data.
Continual model updates: Regularly refined the model with new clinical and pivotal trial data for key comparators.
How Our Practical Agility Keeps Teams Ahead
We operate with an agile structure that enables seamless teamwork and swift resource deployment, ensuring efficient project completion. Our approach included:
- Evidence generation strategy: Performed one-way sensitivity analyses and value of information analyses, providing targeted recommendations for evidence generation based on limited available data.
- Continual model updates: Iteratively refined the model with emerging clinical and pivotal trial data across key comparators to ensure relevance and accuracy.
Customer Testimonies
Why Early Modeling Matters for Pricing & Access
Global price targeting sets realistic pricing expectations before HTA review, identifies critical evidence needs early to guide smarter data collection, and provides flexibility to refine assumptions as data matures. Together, these actions strengthen reimbursement strategies and ensure alignment with payer requirements.
A Step Forward in Strategic Pricing & Access
By combining technical expertise with practical agility, early modeling enables companies to evaluate pricing potential and develop stronger HTA strategies. This proactive approach reduces uncertainty, informs access planning, and increases the likelihood of market success.
Is your HTA strategy built on early pricing insights?
Meet our Modeling Team
Dawn Lee
Strategic Council member
Dawn is a highly experienced health economic modeler with over 50 submissions to the UK Health Technology Assessment. She has worked across more than 30 countries globally and is a member of NICE’s interventional procedures advisory committee and the R for HTA group. Dawn is particularly focused on oncology modeling, immune-oncology, and flexible survival modeling. She also provides training on NICE processes and regularly represents clients at Committee meetings.
Holly Guy
Executive Director
She has extensive experience in HEOR consulting across the product lifecycle and numerous disease areas, including haematology, thrombosis, oncology, infectious diseases, and gastroenterology. She has over 30 successful HTA submissions, including those to NICE, SMC, and AWMSG in the UK, as well as in several European countries. She has attended and represented pharma companies at NICE and AWMSG appraisal committee meetings. She led the team that helped secure regulatory approval for treatment targeting advanced ovarian cancer, marking the first new product to reach the market in nearly 20 years.
Vicki Laskier
Director
Vicki specializes in the strategy and implementation of HEOR solutions. With extensive experience in developing HTA dossiers, systematic literature reviews, and economic models, she has contributed to over 19 HTA submissions across NICE, SMC, and NCPE. Vicki has also represented companies at HTA meetings, leading the development of tools that support both payer and internal needs. Her work in statistical analysis, including Bayesian methods and network meta-regressions, has been widely used in healthcare decision-making.
FAQs on Early Modeling for Price Potential & HTA
- When should early modeling begin?
During late-clinical or pre-launch phases, key inputs are available before full evidence is complete. - What structural settings are typically tested?
Treatment sequence, usage, discontinuation, patient subgroups, and cost/clinical inputs. - How do sensitivity and value of information analyses help?
They highlight which inputs most affect outcomes, guiding evidence generation priorities. - What does the HTA strategy involve in this context?
Critical appraisals, assumption testing, and comparator benchmarking to shape HTA body perceptions. - What are the usual deliverables?
Early cost-effectiveness model, scenario analyses, sensitivity analyses, and updated evidence generation plan.